Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
Abstract Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 1...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-04-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-021-00168-1 |